Company: GRCE
Filing Date: 2025-09-18
Form Type: 8-K
Source: 0001140361-25-035337
Chunk: 0

Company: Grace Therapeutics, Inc.
Filing Date: 2025-09-18
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01.      Other Events.  

On September 18, 2025, Grace Therapeutics, Inc. issued a press release announcing that the U. S. Patent and Trademark Office
issued a Patent No. 12,414,943, titled “ Nimodipine Parenteral Administration.” The new method of use patent, published on September 16, 2025, covers the dosing regimen for I. V. administration of nimodipine used in the Phase 3 STRIVE-ON safety
trial for GTx-104 and extends patent protection for GTx-104 to 2043. GTx-104 is a clinical-stage, novel, injectable formulation of nimodipine being developed for I. V. infusion to address significant unmet medical needs in aneurysmal
subarachnoid hemorrhage patients.

A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by
reference into this Item 8.01.

  Item 9.01.      Financial Statements and Exhibits.